The first Ebola vaccine in China has been approved for clinical research of military special drugs

December 18 Recently, the PLA Academy of Military Medical Sciences announced that the "recombinant Ebola virus vaccine" jointly developed by its affiliated Institute of bioengineering and Tianjin kangxinuo Biotechnology Co., Ltd against Ebola virus has passed the joint review of experts from the PLA General Logistics Department, the Ministry of health and health and relevant national departments, and obtained the approval document for clinical research of special drugs for the military 。 The vaccine will become the third Ebola vaccine in the world to enter the human clinical trial stage after the cad3-zebov vaccine jointly developed by NIAID and GSK in the United States and the vsv-zebov vaccine jointly developed by Public Health Canada and newl ink in the United States in 2014 It is reported that the research team of the Institute of bioengineering of the Academy of Military Medical Sciences of the people's Liberation Army has carried out the research on the Ebola virus vaccine based on the recombinant adenovirus since 2006 After the outbreak of Ebola in 2014, the research team developed the vaccine of Ebola virus based on adenovirus vector for the new virus epidemic strain sequence (Zaire Guinea, 2014) In order to speed up the development of Ebola vaccine, the Institute of bioengineering of the Academy of Military Medical Sciences, together with Tianjin kangxinuo Biotechnology Co., Ltd and China food and drug inspection and Research Institute, jointly tackle key problems and promote the vaccine to enter the clinical research stage as soon as possible Experts said that the vaccine was designed according to the sequence of Zaire Guinea 2014 Ebola virus, which was prevalent in West Africa in 2014, and has a strong pertinence to this outbreak The Ebola vaccines developed in other countries this year are designed for the sequence of Zaire (mayinga, 1976) epidemic strain The vaccine is the world's first freeze-dried dosage form, which can be stable for 2 weeks at 37 ℃, and is more suitable for use in areas with backward conditions and imperfect cold chain in West Africa At present, vaccines entering clinical research stage in foreign countries need to be stored at - 80 ℃ In addition, due to the current large-scale vaccine preparation technology has been more mature, the vaccine can meet the needs of large-scale population in the future